Johnson & Johnson, A ‘wake-up call’ data on the Novax vaccine coronavirus virus

  • Johnson & Johnson and Novavax vaccines have again been less effective for a new virus version.
  • “It’s really a wake-up call for us,” Dr. Anthony Fauci said.
  • People should still be vaccinated as soon as possible, Fauci said.
  • For more stories visit the Business Insider homepage.

Dr. Anthony Fauci said on Friday that the two vaccines have proven less effective against a new version of the virus.

“It will actually continue to be agile for us as well as being able to adjust to the agile and this virus,” said Fauci, director of the National Institute of Allergy and Infections Disease.

He spoke on a conference call that the National Institutes of Health held to discuss the data on Johnson & Johnson’s coronavirus vaccine. J&J stated that its vaccine was 66% effective in preventing moderate and severe cases of COVID-19 overall, but less effective in South Africa, where a virus variant is spreading. Novavax said on Thursday that its coronavirus vaccine was also less effective than that coronavirus version.

On Thursday, the first US cases of that edition were identified.

Fauci said that Americans need to be vaccinated as soon as possible.

During a conversation with other NIH officials and officials, he said, “The best way to prevent further development of the virus is to stop mimicking it, and that you get people vaccinated as soon as possible.” .

Experts previously hoped that COVID vaccines currently available on the market, as well as those under development, would be strong against variants unless there were major changes to the spike protein – a key component of the virus. . But there is a change in that part of the virus in the South African version.

Read more: Modern is designing a new version of its Kovid-19 shot to address a new version

Even two vaccines currently made in the US by Morden and Pfizer may be affected by the new variant. Both companies have stated that their vaccines should still produce sufficient protective antibodies to prevent the virus, although laboratory results have shown that protection may be reduced. As a precaution, Modern and Pfizer are now working on booster shots that can directly target variants.

Leave a Reply

Your email address will not be published.